Feasibility of continuing crizotinib therapy after RECIST-PD in advanced non-small cell lung cancer patients with ALK/ROS-1 mutations

Objectives: To study whether ongoing clinical benefits of continuing anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) inhibition are achieved by crizotinib treatment post progressive disease (PD) in advanced non-small cell lung cancer (NSCLC) patients harboring ALK/ROS1 mutations. Materi...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jun, Cui, Shaohua, Pan, Feng, Ni, Yiqian, Zhong, Hua, Xiong, Liwen, Jin, Bo, Chu, Tianqing, Gu, Aiqin, Jiang, Liyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968775/
https://www.ncbi.nlm.nih.gov/pubmed/29805713
http://dx.doi.org/10.7150/jca.24950

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968775/
https://www.ncbi.nlm.nih.gov/pubmed/29805713
http://dx.doi.org/10.7150/jca.24950

Ejemplares similares